Status:
COMPLETED
Study Evaluating Enbrel in Patients With Rheumatoid Arthritis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to investigate the incidence of adverse events for patients with rheumatoid arthritis treated with Enbrel under usual care settings. In addition, differences in injection ...
Eligibility Criteria
Inclusion
- Proven diagnosis of rheumatoid arthritis
Exclusion
- Contraindications according to Summary of Product Characteristic (SmPC)of Enbrel® the following points will prevent or restrict participation:
- Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®
- Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localized infections
- Patients with sepsis or risk of sepsis should not be treated
Key Trial Info
Start Date :
June 1 2003
Trial Type :
OBSERVATIONAL
End Date :
July 1 2005
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT00245934
Start Date
June 1 2003
End Date
July 1 2005
Last Update
December 14 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.